InsiderTrades.com logo
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>
Donna Hildebrand Kralowetz net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Donna Kralowetz Biography and Net Worth

CAO of Syneos Health
Donna Hildebrand Kralowetz is the Sr. VP of Fin. & Principal Accounting Officer at Syneos Health Inc.

What is Donna Hildebrand Kralowetz's net worth?

The estimated net worth of Donna Hildebrand Kralowetz is at least $292,478.90 as of July 8th, 2022. Ms. Kralowetz owns 6,805 shares of Syneos Health stock worth more than $292,479 as of April 19th. This net worth approximation does not reflect any other assets that Ms. Kralowetz may own. Learn More about Donna Hildebrand Kralowetz's net worth.

How old is Donna Hildebrand Kralowetz?

Ms. Kralowetz is currently 52 years old. There are 7 older executives and no younger executives at Syneos Health. The oldest executive at Syneos Health is Ms. Michelle Keefe, CEO & Director, who is 56 years old. Learn More on Donna Hildebrand Kralowetz's age.

How do I contact Donna Hildebrand Kralowetz?

The corporate mailing address for Ms. Kralowetz and other Syneos Health executives is 1030 Sync Street, Morrisville NC, 27560. Syneos Health can also be reached via phone at (919) 876-9300 and via email at [email protected]. Learn More on Donna Hildebrand Kralowetz's contact information.

Has Donna Hildebrand Kralowetz been buying or selling shares of Syneos Health?

Donna Hildebrand Kralowetz has not been actively trading shares of Syneos Health during the past quarter. Most recently, Donna Hildebrand Kralowetz sold 1,149 shares of the business's stock in a transaction on Friday, July 8th. The shares were sold at an average price of $73.16, for a transaction totalling $84,060.84. Following the completion of the sale, the chief accounting officer now directly owns 6,805 shares of the company's stock, valued at $497,853.80. Learn More on Donna Hildebrand Kralowetz's trading history.

Who are Syneos Health's active insiders?

Syneos Health's insider roster includes Michael Brooks (Insider), John Dineen (Director), Linda Harty (Director), Michelle Keefe (Insider), Donna Kralowetz (CAO), Alistair Macdonald (CEO), John Maldonado (Director), Jason Meggs (CFO), Matthew Monaghan (Director), and Jonathan Olefson (General Counsel). Learn More on Syneos Health's active insiders.

Donna Hildebrand Kralowetz Insider Trading History at Syneos Health

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/8/2022Sell1,149$73.16$84,060.846,805View SEC Filing Icon  
1/31/2022Sell1,055$90.00$94,950.00View SEC Filing Icon  
9/3/2021Sell248$94.30$23,386.40View SEC Filing Icon  
6/18/2021Sell590$85.03$50,167.707,057View SEC Filing Icon  
See Full Table

Donna Hildebrand Kralowetz Buying and Selling Activity at Syneos Health

This chart shows Donna Hildebrand Kralowetz's buying and selling at Syneos Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Syneos Health Company Overview

Syneos Health logo
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.
Read More

Today's Range

Now: $42.98
Low: $42.97
High: $42.99

50 Day Range

MA: $42.86
Low: $42.48
High: $42.98

2 Week Range

Now: $42.98
Low: $22.89
High: $52.23

Volume

7,386,200 shs

Average Volume

1,924,736 shs

Market Capitalization

$4.46 billion

P/E Ratio

62.29

Dividend Yield

N/A

Beta

1.58
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>